IGAN
Clinical trials for IGAN explained in plain language.
Never miss a new study
Get alerted when new IGAN trials appear
Sign up with your email to follow new studies for IGAN, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill aims to slow kidney disease in IgA nephropathy patients
Disease control Recruiting nowThis study tests an experimental drug called STL303 for people with IgA nephropathy, a kidney disease. About 15 adults will receive either STL303 or a placebo to see if the drug is safe and can reduce protein in the urine, a sign of kidney damage. Possible side effects include na…
Matched conditions: IGAN
Phase: PHASE2 • Sponsor: Sitala Bio LTD • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New hope for kids with kidney disease: drug trial targets protein leak
Disease control Recruiting nowThis study tests a drug called ravulizumab in children aged 2 to 18 with a kidney disease called IgA nephropathy. The goal is to see if the drug can reduce protein in the urine, a sign of kidney damage. Participants will receive the drug through an IV and be monitored for safety …
Matched conditions: IGAN
Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
New siRNA drug aims to tame kidney disease
Disease control Recruiting nowThis Phase 2 study is testing a new drug called ADX-038 in 45 adults with complement-mediated kidney diseases, such as IgA nephropathy and C3G. The drug is an siRNA that targets the complement system, which is overactive in these conditions. Researchers are checking if it is safe…
Matched conditions: IGAN
Phase: PHASE2 • Sponsor: ADARx Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
New drug aims to calm immune attacks on kidneys
Disease control Recruiting nowThis Phase 2 study tests atacicept, a drug that may reduce immune system attacks on the kidneys. About 250 adults with various autoimmune kidney diseases (like IgA nephropathy or membranous nephropathy) will receive weekly injections. Researchers will check safety and measure cha…
Matched conditions: IGAN
Phase: PHASE2 • Sponsor: Vera Therapeutics, Inc. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC